MacroGenics reports Q1 loss, divests manufacturing, extends cash runway through 2028

MACROGENICS INC

Manufacturing operations sold to Bora Pharmaceuticals for $122.5M upfront; expected to close Q3 2026.
Expanded ZYNYZ royalty monetization with Sagard: $60M received, up to $20M additional milestone.
Q1 2026 net loss $36.8M ($0.58/share) vs $41.0M loss a year ago; revenue $20.8M (up from $13.2M).
Cash and securities $154.2M at March 31, 2026; with proceeds, cash runway extended through 2028.
Pipeline: Initial MGC026 ADC data expected mid-2026; MGC028 data H2 2026; MGC030 IND planned Q3 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MACROGENICS INC reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 13, 2026, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2026.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

MACROGENICS INC filing history →

Source: SEC EDGAR

accession 0001125345-26-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.